Document Detail


Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
MedLine Citation:
PMID:  23122768     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease.
METHODS: We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline to week 26, after which patients remained on lomitapide through to week 78 for safety assessment. Percent change from baseline to week 26 was assessed with a mixed linear model.
FINDINGS: 29 men and women with homozygous familial hypercholesterolaemia, aged 18 years or older, were recruited from 11 centres in four countries (USA, Canada, South Africa, and Italy). 23 of 29 enrolled patients completed both the efficacy phase (26 weeks) and the full study (78 weeks). The median dose of lomitapide was 40 mg a day. LDL cholesterol was reduced by 50% (95% CI -62 to -39) from baseline (mean 8·7 mmol/L [SD 2·9]) to week 26 (4·3 mmol/L [2·5]; p<0·0001). Levels of LDL cholesterol were lower than 2·6 mmol/L in eight patients at 26 weeks. Concentrations of LDL cholesterol remained reduced by 44% (95% CI -57 to -31; p<0·0001) at week 56 and 38% (-52 to -24; p<0·0001) at week 78. Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase levels of more than five times the upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities.
INTERPRETATION: Our study suggests that treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia.
FUNDING: FDA Office of the Orphan Product Development, Aegerion Pharmaceuticals.
Authors:
Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader;
Related Documents :
18547498 - The duration of clinical remission of photochemotherapy and narrow-band uv-b photothera...
2931938 - Hand eczema and long-term prognosis in atopic dermatitis.
9403258 - New successful treatment with disinfectant for atopic dermatitis.
15450338 - Current concepts and review of efalizumab in the treatment of psoriasis.
23203338 - Short-term functional and clinical outcomes after acl reconstruction with hamstrings au...
16243418 - Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine wit...
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2012-11-02
Journal Detail:
Title:  Lancet     Volume:  381     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-07     Completed Date:  2013-01-24     Revised Date:  2013-04-09    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  40-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Affiliation:
Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA. mcuchel@mail.med.upenn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Benzimidazoles / adverse effects,  therapeutic use*
Carrier Proteins / antagonists & inhibitors*
Cholesterol, LDL / blood
Female
Homozygote
Humans
Hyperlipoproteinemia Type II / blood,  drug therapy*,  genetics
Male
Grant Support
ID/Acronym/Agency:
UL1-RR-024134/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/BMS201038; 0/Benzimidazoles; 0/Carrier Proteins; 0/Cholesterol, LDL; 0/microsomal triglyceride transfer protein
Investigator
Investigator/Affiliation:
M Cuchel / ; E A Meagher / ; D M Kolansky / ; B S Sachais / ; P K Shah / ; D J Blom / ; A D Marais / ; H du T Theron / ; A M E du Plessis / ; D Gaudet / ; R A Hegele / ; A B Cefalù / ; D Noto / ; M R Averna / ; C R Sirtori / ; A Bondioli / ; M Triolo / ; G Mombelli / ; G B Vigna / ; E Lodi / ; E Menegatti / ; E Tosini / ; C Stefanutti / ; S Di Giacomo /
Comments/Corrections
Comment In:
Lancet. 2013 Apr 6;381(9873):1183   [PMID:  23561998 ]
Lancet. 2013 Apr 6;381(9873):1182   [PMID:  23561997 ]
Lancet. 2013 Jan 5;381(9860):7-8   [PMID:  23122767 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of sewage nutrients on algal production, biomass and pigments in tropical tidal creeks.
Next Document:  Bone mineral density and blood metals in premenopausal women.